|
| Status |
Public on Jun 12, 2018 |
| Title |
Y537S Fulvestrant rep3 |
| Sample type |
RNA |
| |
|
| Source name |
Y537S.Ful.3
|
| Organism |
Homo sapiens |
| Characteristics |
cell line: MCF7
er-alpha mutation: Y537S
treatment: Fulvestrant
|
| Treatment protocol |
Cells were treated with DMSO or test compounds for ~16h.
|
| Growth protocol |
Engineered MCF7 lines were cultured in media supplemented with 10% FBS.
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Total RNA was extracted using the RNeasy Mini Kit.
|
| Label |
biotin
|
| Label protocol |
Standard Affymetrix protocol
|
| |
|
| Hybridization protocol |
Samples were hybridized for 16 hours at 45 C, 60 RPMs onto U133 Plus 2.0 human genome arrays
|
| Scan protocol |
After washing the chips in the Affymetrix Fluidics System 450, they were scanned using the GeneChip 30007G Scanner
|
| Data processing |
The data were analyzed with robust multi-array average (RMA) using default analysis settings
|
| |
|
| Submission date |
Jun 11, 2018 |
| Last update date |
Jun 12, 2018 |
| Contact name |
Zhenhua Wu |
| E-mail(s) |
zhenhuawu75@gmail.com
|
| Phone |
6179592279
|
| Organization name |
H3 Biomedicine
|
| Street address |
300 Technology Square floor 5
|
| City |
Cambridge |
| State/province |
MA |
| ZIP/Postal code |
02139 |
| Country |
USA |
| |
|
| Platform ID |
GPL570 |
| Series (2) |
| GSE115564 |
ESR1 mutations maintain higher ER pathway activity relative to vehicle and ERa-WT controls following treatment with Raloxifene or fulvestrant. |
| GSE115611 |
Discovery of Selective Estrogen Receptor Covalent Antagonists (SERCAs) for the treatment of ERa(WT) and ERa(MUT) breast cancer. |
|
